Genglycos Gene Therapy Wins FDA Approval for Glycogen Storage Disease Type Ia

The U.S. Food and Drug Administration has granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy developed by Ultragenyx Pharmaceutical Inc. for adults and children aged 8 years and older living with glycogen storage disease type Ia, or GSDIa. The approval marks an important development for people affected by this ultra-rare inherited metabolic disorder, particularly because the treatment is designed to reduce the daily dependence on raw cornstarch as part of nutritional management.

What Is Glycogen Storage Disease Type Ia?

GSDIa is a rare genetic metabolic disorder caused by pathogenic variants in the G6PC gene. The gene provides instructions for an enzyme called glucose-6-phosphatase, which plays an important role in releasing glucose from glycogen and other metabolic sources.

When this enzyme is deficient, the liver cannot adequately release glucose into the bloodstream during fasting. As a result, people with GSDIa can experience severe hypoglycemia, particularly between meals and overnight. The condition can also lead to excess glycogen accumulation in the liver and other metabolic complications.

GSDIa is considered ultra-rare. According to the information supporting the Genglycos approval, the condition affects approximately 1,500 to 2,500 people in the United States and about 6,000 to 8,000 people worldwide within commercially accessible geographies.

Why Cornstarch Has Been So Important

For many people with GSDIa, nutritional management has traditionally been central to maintaining safe blood glucose levels. Raw cornstarch provides an external source of glucose and is taken regularly throughout the day and night to help prevent dangerous drops in blood sugar.

However, this approach can be demanding for patients and families. Maintaining a strict schedule may require frequent doses, dietary planning and overnight vigilance. Even with careful management, glucose levels can fluctuate, and missing a scheduled dose can potentially result in severe hypoglycemia.

The FDA indication for Genglycos is specifically to reduce daily cornstarch intake as an adjunct to nutritional management in adults and pediatric patients aged 8 years and older with GSDIa. This means the therapy is intended to work alongside nutritional care rather than simply replace the need for medical and dietary management.

How Genglycos Was Evaluated

The approval was supported by results from the 48-week randomized, double-blind, placebo-controlled Phase 3 GlucoGene study. The trial included 46 participants aged 8 years and older who received either DTX401, the therapy that became Genglycos, or placebo.

The study reported a significant reduction in cornstarch requirements among participants receiving treatment. The source reports a p-value of less than 0.001 for the reduction. After the initial 48-week period, eligible participants crossed over to receive the alternate treatment and continued to be followed, with analyses conducted at Weeks 96 and 144.

The FDA granted accelerated approval based on the reduction in daily cornstarch intake. Under this pathway, continued approval may depend on confirmation of clinical benefit through additional studies.

What Happens After Approval?

The approval includes post-marketing requirements intended to provide additional information about Genglycos in routine clinical use.

Ultragenyx has agreed to provide two years of safety and efficacy data from open-label commercial treatment involving 50 patients and 20 control patients through an enhanced GSDIa Disease Monitoring Program. The control group will include patients who sought commercial treatment but cannot receive Genglycos because they have anti-AAV8 antibodies.

The monitoring program will examine measures including cornstarch burden and fasting tolerance. Previously treated clinical trial participants and newly treated commercial patients are expected to be followed for a total of 10 years.

Important Safety Information

Although the approval represents a significant development in GSDIa treatment, Genglycos has important safety considerations.

The therapy is contraindicated in patients with known severe hepatic fibrosis or cirrhosis. Hypersensitivity reactions and infusion reactions, including severe reactions and anaphylaxis, have been reported. Patients are monitored during and after infusion, and appropriate medical support must be available during administration.

Hepatotoxicity is another important concern. Immune-mediated liver injury, including elevated ALT and AST levels, has occurred following treatment. Liver function is assessed before treatment, and transaminase levels are monitored for the first six months after administration. Corticosteroid treatment is used following infusion to help reduce hepatic reactions.

Adrenal insufficiency has also been reported during corticosteroid treatment and tapering. Patients need appropriate monitoring, and corticosteroids should be tapered gradually rather than stopped suddenly.

The prescribing information also notes a theoretical tumorigenicity risk associated with integration of AAV vector DNA into the human genome. Genglycos uses a recombinant, non-replicating AAV8 vector, with its DNA persisting largely in episomal form, but random integration events have been reported with AAV gene therapies.

What This Approval Could Mean for Patients

For families affected by GSDIa, reducing dependence on frequent cornstarch dosing could potentially ease some of the practical demands associated with disease management. The treatment is particularly notable because it represents a gene therapy approach intended to address an underlying biological problem rather than relying solely on dietary glucose replacement.

At the same time, Genglycos does not eliminate the need for specialist care. Its approved use is as an adjunct to nutritional management, and patients require monitoring for potential adverse reactions and other safety concerns.

Ultragenyx plans to make Genglycos available through a national network of Qualified Treatment Centers with specialized training in administering gene therapy. The company has also established an UltraCare program intended to help eligible patients and caregivers navigate treatment access, insurance coverage and treatment support.

A New Chapter in GSDIa Treatment

The FDA approval of Genglycos represents a notable milestone in the development of treatments for glycogen storage disease type Ia. For a community that has historically depended on demanding nutritional schedules to manage the risk of hypoglycemia, a therapy capable of reducing daily cornstarch requirements could offer a meaningful change in disease management.

However, because the approval is accelerated, additional evidence will be important in determining the long-term clinical benefit of the treatment. Ongoing monitoring and post-marketing studies will help provide a clearer picture of its effectiveness, durability and safety in broader patient populations.

For patients and families, the approval provides a new therapeutic option while also highlighting the continuing importance of specialized medical supervision, nutritional management and long-term follow-up.

Source

Ultragenyx Pharmaceutical Inc.

Medical Disclaimer

This article is provided for general educational and informational purposes only. It is not intended to provide medical advice, diagnosis or treatment recommendations. Genglycos is a prescription gene therapy with important risks and eligibility requirements. Patients and caregivers should speak with a qualified healthcare professional for advice about GSDIa, treatment options, potential benefits and risks. Information about medicines can change as additional clinical and regulatory data become available.